Tae Hyong Kim1, Jieun Song1, Sung-Hak Kim1, Arav Krishnavadan Parikh1, Xiaokui Mo1, Kamalakannan Palanichamy1, Balveen Kaur1, Jianhua Yu1, Sung Ok Yoon1, Ichiro Nakano1, Chang-Hyuk Kwon1. 1. Dardinger Neuro-oncology Center, Department of Neurological Surgery, Ohio State University, Columbus, Ohio (T.H.K., J.S., S.-H.K., A.K.P., I.N., B.K., C.-H.K.); Solid Tumor Program at the James Comprehensive Cancer Center, Columbus, Ohio (T.H.K., J.S., A.K.P., C.-H.K.); Center for Biostatistics, Ohio State University, Columbus, Ohio (X.M.); Department of Radiation Oncology, Ohio State University, Columbus, Ohio (K.P.); Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio (J.Y.); Department of Molecular and Cellular Biochemistry, Ohio State University Wexner Medical Center, Columbus, Ohio (S.O.Y.).
Abstract
BACKGROUNDS: Piperlongumine, a natural plant product, kills multiple cancer types with little effect on normal cells. Piperlongumine raises intracellular levels of reactive oxygen species (ROS), a phenomenon that may underlie the cancer-cell killing. Although these findings suggest that piperlongumine could be useful for treating cancers, the mechanism by which the drug selectively kills cancer cells remains unknown. METHODS: We treated multiple high-grade glioma (HGG) sphere cultures with piperlongumine and assessed its effects on ROS and cell-growth levels as well as changes in downstream signaling. We also examined the levels of putative piperlongumine targets and their roles in HGG cell growth. RESULTS: Piperlongumine treatment increased ROS levels and preferentially killed HGG cells with little effect in normal brain cells. Piperlongumine reportedly increases ROS levels after interactions with several redox regulators. We found that HGG cells expressed higher levels of the putative piperlongumine targets than did normal neural stem cells (NSCs). Furthermore, piperlongumine treatment in HGG cells, but not in normal NSCs, increased oxidative inactivation of peroxiredoxin 4 (PRDX4), an ROS-reducing enzyme that is overexpressed in HGGs and facilitates proper protein folding in the endoplasmic reticulum (ER). Moreover, piperlongumine exacerbated intracellular ER stress, an effect that was mimicked by suppressing PRDX4 expression. CONCLUSIONS: Our results reveal that the mechanism by which piperlongumine preferentially kills HGG cells involves PRDX4 inactivation, thereby inducing ER stress. Therefore, piperlongumine treatment could be considered as a novel therapeutic option for HGG treatment.
BACKGROUNDS: Piperlongumine, a natural plant product, kills multiple cancer types with little effect on normal cells. Piperlongumine raises intracellular levels of reactive oxygen species (ROS), a phenomenon that may underlie the cancer-cell killing. Although these findings suggest that piperlongumine could be useful for treating cancers, the mechanism by which the drug selectively kills cancer cells remains unknown. METHODS: We treated multiple high-grade glioma (HGG) sphere cultures with piperlongumine and assessed its effects on ROS and cell-growth levels as well as changes in downstream signaling. We also examined the levels of putative piperlongumine targets and their roles in HGG cell growth. RESULTS:Piperlongumine treatment increased ROS levels and preferentially killed HGG cells with little effect in normal brain cells. Piperlongumine reportedly increases ROS levels after interactions with several redox regulators. We found that HGG cells expressed higher levels of the putative piperlongumine targets than did normal neural stem cells (NSCs). Furthermore, piperlongumine treatment in HGG cells, but not in normal NSCs, increased oxidative inactivation of peroxiredoxin 4 (PRDX4), an ROS-reducing enzyme that is overexpressed in HGGs and facilitates proper protein folding in the endoplasmic reticulum (ER). Moreover, piperlongumine exacerbated intracellular ER stress, an effect that was mimicked by suppressing PRDX4 expression. CONCLUSIONS: Our results reveal that the mechanism by which piperlongumine preferentially kills HGG cells involves PRDX4 inactivation, thereby inducing ER stress. Therefore, piperlongumine treatment could be considered as a novel therapeutic option for HGG treatment.
Authors: Stefan J Marciniak; Chi Y Yun; Seiichi Oyadomari; Isabel Novoa; Yuhong Zhang; Rivka Jungreis; Kazuhiro Nagata; Heather P Harding; David Ron Journal: Genes Dev Date: 2004-12-15 Impact factor: 11.361
Authors: Chang-Hyuk Kwon; Dawen Zhao; Jian Chen; Sheila Alcantara; Yanjiao Li; Dennis K Burns; Ralph P Mason; Eva Y-H P Lee; Hong Wu; Luis F Parada Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Sofia Papadia; Francesc X Soriano; Frédéric Léveillé; Marc-Andre Martel; Kelly A Dakin; Henrik H Hansen; Angela Kaindl; Marco Sifringer; Jill Fowler; Vanya Stefovska; Grahame McKenzie; Marie Craigon; Roderick Corriveau; Peter Ghazal; Karen Horsburgh; Bruce A Yankner; David J A Wyllie; Chrysanthy Ikonomidou; Giles E Hardingham Journal: Nat Neurosci Date: 2008-03-23 Impact factor: 24.884
Authors: Wayne Harshbarger; Sudershan Gondi; Scott B Ficarro; John Hunter; Durga Udayakumar; Deepak Gurbani; William D Singer; Yan Liu; Lianbo Li; Jarrod A Marto; Kenneth D Westover Journal: J Biol Chem Date: 2016-11-21 Impact factor: 5.157
Authors: Di Chen; Xinyue Wei; Ke Yang; Xinyue Liu; Yujin Song; Futing Bai; Yi Jiang; Yuhang Guo; Rajiv Kumar Jha Journal: J Int Med Res Date: 2022-04 Impact factor: 1.573
Authors: Yong Chen; Ju Mei Liu; Xin Xin Xiong; Xin Yao Qiu; Feng Pan; Di Liu; Shu Jue Lan; Si Jin; Shang Bin Yu; Xiao Qian Chen Journal: Oncotarget Date: 2015-03-20
Authors: Fernanda de Lima Moreira; Maísa D Habenschus; Thiago Barth; Lucas M M Marques; Alan Cesar Pilon; Vanderlan da Silva Bolzani; Ricardo Vessecchi; Norberto P Lopes; Anderson R M de Oliveira Journal: Sci Rep Date: 2016-09-29 Impact factor: 4.379